NeoTherapeutics Receives Patent Allowance for Technology That May Lead To New Treatments for Neuropathic Pain, Obesity, Anxiety and Depression

Apr 24, 2001, 01:00 ET from NeoTherapeutics, Inc.

    IRVINE, Calif., April 24 /PRNewswire Interactive News Release/ --
 NeoTherapeutics, Inc. (Nasdaq:   NEOT, NEOTW) announced today that the Company
 has been allowed a new U.S. patent covering its hypoxanthine-based
 bifunctional molecule technology platform. The new patent covers additional
 hypoxanthine-based compounds that have serotonin-like characteristics.
     "We have broadened our technology platform for purine-based compounds
 through the allowance of this patent for serotonin-like derivatives of
 hypoxanthine," stated Michelle S. Glasky, Ph.D., Vice President, Scientific
 Affairs of NeoTherapeutics. "Our Drug Discovery Group is growing and so are
 the number of patents that we are allowed and issued, as well as the number of
 patent applications we are filing on new technologies. We are expanding our
 drug development efforts, and the allowance of this patent is a step in
 creating new drugs that may impact the serotonin system for diseases such as
 neuropathic pain, obesity, anxiety and depression."
     Previously, the United States Patent and Trademark Office granted
 NeoTherapeutics four patents covering the Company's technology platform, which
 includes NeoTherapeutics' lead drug candidate, Neotrofin(TM). NeoTherapeutics
 has 15 additional patent applications pending in the U.S. as well as patent
 applications in development for additional technologies. NeoTherapeutics has
 also filed, and in some cases received, international patent applications
 corresponding to its U.S. patents to further expand its technology base.
     NeoTherapeutics is a biopharmaceutical company focused on the development
 of drugs for unmet medical needs. The Company's most advanced drug,
 Neotrofin(TM), is currently being developed for Alzheimer's disease and other
 neurodegenerative diseases, such as Parkinson's disease and spinal cord
 injury. NeoTherapeutics creates value for shareholders through the development
 of central nervous system drugs by its neurology division, in-licensing and
 development of anti-cancer drugs through its NeoOncoRx subsidiary, and the
 licensing out of new drug targets through its NeoGene Technologies subsidiary.
 For additional information visit the Company's web site at
 www.neotherapeutics.com.
 
     This press release may contain forward-looking statements regarding future
 events and the future performance of NeoTherapeutics that involve risks and
 uncertainties that could cause actual results to differ materially. These
 risks are described in further detail in the Company's reports filed with the
 Securities and Exchange Commission.
 
      Contacts:
      MEDIA RELATIONS
      Jon Siegal
      Ronald Trahan Associates (RTA) Inc.
      (508) 647-9782, ext. 15
 
      INVESTOR RELATIONS
      John McManus
      NeoTherapeutics, Inc.
      (949) 788-6700, ext. 247
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X48863954
 
 

SOURCE NeoTherapeutics, Inc.
    IRVINE, Calif., April 24 /PRNewswire Interactive News Release/ --
 NeoTherapeutics, Inc. (Nasdaq:   NEOT, NEOTW) announced today that the Company
 has been allowed a new U.S. patent covering its hypoxanthine-based
 bifunctional molecule technology platform. The new patent covers additional
 hypoxanthine-based compounds that have serotonin-like characteristics.
     "We have broadened our technology platform for purine-based compounds
 through the allowance of this patent for serotonin-like derivatives of
 hypoxanthine," stated Michelle S. Glasky, Ph.D., Vice President, Scientific
 Affairs of NeoTherapeutics. "Our Drug Discovery Group is growing and so are
 the number of patents that we are allowed and issued, as well as the number of
 patent applications we are filing on new technologies. We are expanding our
 drug development efforts, and the allowance of this patent is a step in
 creating new drugs that may impact the serotonin system for diseases such as
 neuropathic pain, obesity, anxiety and depression."
     Previously, the United States Patent and Trademark Office granted
 NeoTherapeutics four patents covering the Company's technology platform, which
 includes NeoTherapeutics' lead drug candidate, Neotrofin(TM). NeoTherapeutics
 has 15 additional patent applications pending in the U.S. as well as patent
 applications in development for additional technologies. NeoTherapeutics has
 also filed, and in some cases received, international patent applications
 corresponding to its U.S. patents to further expand its technology base.
     NeoTherapeutics is a biopharmaceutical company focused on the development
 of drugs for unmet medical needs. The Company's most advanced drug,
 Neotrofin(TM), is currently being developed for Alzheimer's disease and other
 neurodegenerative diseases, such as Parkinson's disease and spinal cord
 injury. NeoTherapeutics creates value for shareholders through the development
 of central nervous system drugs by its neurology division, in-licensing and
 development of anti-cancer drugs through its NeoOncoRx subsidiary, and the
 licensing out of new drug targets through its NeoGene Technologies subsidiary.
 For additional information visit the Company's web site at
 www.neotherapeutics.com.
 
     This press release may contain forward-looking statements regarding future
 events and the future performance of NeoTherapeutics that involve risks and
 uncertainties that could cause actual results to differ materially. These
 risks are described in further detail in the Company's reports filed with the
 Securities and Exchange Commission.
 
      Contacts:
      MEDIA RELATIONS
      Jon Siegal
      Ronald Trahan Associates (RTA) Inc.
      (508) 647-9782, ext. 15
 
      INVESTOR RELATIONS
      John McManus
      NeoTherapeutics, Inc.
      (949) 788-6700, ext. 247
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X48863954
 
 SOURCE  NeoTherapeutics, Inc.